Orexo

Egetis attracts a bid and agrees to sell its priority review voucher, Lytix meets its endpoint in melanoma and Novo raises its outlook – the Nordic Pulse | 2026:45

Xbrane clears the FDA, BioInvent seeks 430 Mkr and Genmab keeps surging – the Nordic Pulse | 2026:44

Ascendis gets the nod in Europe and Camurus wins Canada as Nordic outperformance widens – the Nordic Pulse | 2026:42

Nålfri semaglutid och pivotal studie i sikte när Orexo reser kapital

Orexo har de senaste veckorna tagit flera steg...

Zealand wins in obesity, Genmab hits first-line DLBCL and Oncopeptides crosses the blood-brain barrier – the Nordic Pulse | 2026:41

Egetis wins FDA approval, Indices retreat across the board – the Nordic Pulse | 2026:40

A quarter of billion-euro licences, a Novo comeback and a flat Nordic index – the State of Nordic BioPharma | 2026:Q3

AstraZeneca’s hat-trick, a broad sell-off and Alzinova funds its Alzheimer’s push – the Nordic Pulse | 2026:37

BARDA utökar finansieringen av Orexos överdosläkemedel OX390

Orexos amerikanska dotterbolag har fått ett utökat kontrakt...

Orexo nära förlikning med amerikanska justitiedepartementet

Orexo har nått en icke-bindande principöverenskommelse om de...

Leqembi under the skin, Wegovy wins Europe, Sobi lifts guidance – the Nordic Pulse | 2026:29